Correlation Between Serum Adenosine Deaminase Activity and Efficacy of Anti-Programmed Cell Death-1 Antibody

Immune checkpoint inhibitors represent an important development in the treatment of advanced cancers. In cases of non-small cell lung cancer (NSCLC), the effectiveness of anti –programmed cell death-1 (PD-1) antibody therapies such as nivolumab [1] or pembrolizumab [2] has been demonstrated in several clinical trials. However, the response to anti–PD-1 therapy differed from responses to previous treatments, which included durable response, slow response, pseudoprogres sion and hyperprogression. Such unconventional response patterns made it difficult to differentiate patients who responded to treatment from those who did not respond on the basis of imaging results in the early stages of treatment.

Source: Lung Cancer - April 26, 2019 Category: Cancer & Oncology Authors: Masafumi Saiki, Takahiro Yoshizawa, Yosuke Dotsu, Ryo Ariyasu, Junji Koyama, Tomoaki Sonoda, Ken Uchibori, Shingo Nishikawa, Satoru Kitazono, Noriko Yanagitani, Atsushi Horiike, Makoto Nishio Source Type: research